<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221205056718N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-25</date_registration>
      <primary_sponsor>Ghoum University of Medical Sciences</primary_sponsor>
      <public_title>effect of aromatherapy with peppermint essential oil on pain and  Hemodynamic parameters in patients with acute coronary syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Survey the effect of aromatherapy with peppermint essential oil on pain and  Hemodynamic parameters in patients with acute coronary syndrome (ACS)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>170</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67257</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients who are eligible for the study are entered into the study using the available method and are randomly assigned to two intervention and control groups using the block method (blocks of four and with an allocation ratio of 1:1 using a random number table). . For example, the first four participants enrolled form the first block and the next four form the next block, and so randomization occurs within blocks, so with blocks of size four there are six possible patterns: AABB, ABAB, ABBA , BAAB, BABA, and BBAA, each block is randomized based on one of these six patterns, and the patterns are chosen randomly and generally independently from block to block.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Diseases of the circulatory system. Condition 2: complementary medicine. Condition 3: Pain and hemodynamic symptoms. Condition 4: anxiety.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Peppermint essential oil of Barij company is 0.2 ml of 100% essential oil that they inhale on the eye pads. Mint essential oil and placebo with similar appearance produced by Barij Essan Daru Company are placed in dark bottles with similar sizes and shapes. Aromatherapy for the control group and the intervention group in different places and periods of different uses related to acute stress, treatment, hemodynamic treatments and the intensity of chest pain before aromatherapy (time 1), 5 (time 2) and 15 (time) 3) minutes, 30 minutes after aromatherapy (time 4) after the first stage of aromatherapy, then after 30 minutes (1 hour of aromatherapy) the numbers of the study will be measured (time 5) and the second stage of aromatherapy The patient will be exposed to aromatherapy for 20 minutes. Changes in the study will be recorded at 5 (time 6) and 15 (time 7) and 30 minutes after the second phase of aromatherapy (time 8). Intervention 2: In the control group, the patients will be treated with a non-absorbent eye pad with 0.2 ml of normal saline for 20 minutes, and for the intervention group, the same steps will be performed in another room, but instead of normal saline, the peppermint essential oil of Barij Essance Company will be used. 0.2 ml with a concentration of 100% is used on the pads, and in both groups the desired pads are attached to the clothes of the patients in the chest area by a pin.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after de-identifying individuals

When:
The second half of 1402

To whom:
There is no restriction on access to the results

Conditions:
There are no restrictions after de-identifying people

Where to obtain:
hossein sharafi 
tell:00989173596990
h_sharafi68@yahoo.com

How to obtain:
There are no restrictions

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hossein Sharafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Qom University of Medical Sciences ,pardisan</address>
        <city>Qom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3749153434</zip>
        <telephone>009892531971087</telephone>
        <email>h_sharafi68@yahoo.com</email>
        <affiliation>Ghoum University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hossein Sharafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pardisan,Qom University of Medical Sciences</address>
        <city>Qom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3749153434</zip>
        <telephone>+98 25 3197 1087</telephone>
        <email>h_sharafi68@yahoo.com</email>
        <affiliation>Ghoum University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Full consciousness
Age range 18-60 years
Absence of valvular heart disease
Severe disease conditions
Any vision, hearing, or smell disorder
Absence of respiratory and allergic problems
No drug addiction
Absence of liver and kidney problems
Not taking sedatives 4 hours before the intervention
No history of any confirmed mental illness such as depression, anxiety, stress</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Sudden occurrence of any severe changes in vital signs and the presence of dangerous cardiac dysrhythmias in patients
Unwillingness to continue participating in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I20.1</hc_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
      <hc_code>F41.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Angina pectoris with documented spasm</hc_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword>Anxiety disorder, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Peppermint essential oil of Barij company is 0.2 ml of 100% essential oil that they inhale on the eye pads. Mint essential oil and placebo with similar appearance produced by Barij Essan Daru Company are placed in dark bottles with similar sizes and shapes. Aromatherapy for the control group and the intervention group in different places and periods of different uses related to acute stress, treatment, hemodynamic treatments and the intensity of chest pain before aromatherapy (time 1), 5 (time 2) and 15 (time) 3) minutes, 30 minutes after aromatherapy (time 4) after the first stage of aromatherapy, then after 30 minutes (1 hour of aromatherapy) the numbers of the study will be measured (time 5) and the second stage of aromatherapy The patient will be exposed to aromatherapy for 20 minutes. Changes in the study will be recorded at 5 (time 6) and 15 (time 7) and 30 minutes after the second phase of aromatherapy (time 8).</i_keyword>
      <i_keyword>In the control group, the patients will be treated with a non-absorbent eye pad with 0.2 ml of normal saline for 20 minutes, and for the intervention group, the same steps will be performed in another room, but instead of normal saline, the peppermint essential oil of Barij Essance Company will be used. 0.2 ml with a concentration of 100% is used on the pads, and in both groups the desired pads are attached to the clothes of the patients in the chest area by a pin.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain related to aromatherapy. Timepoint: Before and immediately after intervention. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Anxiety related to aromatherapy. Timepoint: Before and immediately after intervention. Method of measurement: Depression Anxiety and Stress Scale 21 (DASS-21).</prim_outcome>
      <prim_outcome>Hemodynamic parameters. Timepoint: Before and immediately after intervention. Method of measurement: Digital heart monitoring system.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ghoum University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-11-21</approval_date>
        <contact_name>Research Ethics Committee of Qom University of Medical Sciences</contact_name>
        <contact_address>No. 83, Safashehr St., Shahid Lotfi Niaser- Shahid Lotfi Niaser Alley, Safashehr Street, Qom Qom Ghoum Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
